COVID-19 in Sarcoidosis Patients
Attapon Cheepsattayakorn*, Porntep Siriwanarangsun and Ruangrong Cheepsattayakorn
Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai, 50100, Thailand.
Received: January 03, 2024; Revised: February 16, 2024; Accepted: February 19, 2024 Available Online: March 08, 2024
Citation: Cheepsattayakorn A, Siriwanarangsun P & Cheepsattayakorn R. (2024) COVID-19 in Sarcoidosis Patients. J Infect Dis Res, 7(1): 348-352.
Copyrights: ©2024 Cheepsattayakorn A, Siriwanarangsun P & Cheepsattayakorn R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 87

    Views & Citations
  • 10

    Likes & Shares

Several post-COVID-19 inflammatory disorders and autoimmune diseases have been discovered [1] since global COVID-19 pandemic started [2]. Association between these diseases is still to be investigated [2]. Common genes between COVID-19 and sarcoidosis are demonstrated in Figures 1 & 2 [3]. Nevertheless, sarcoidosis organ involvement, demographics, and type of sarcoidosis treatment at the time of COVID-19 diagnosis are related to hospital admission, non-invasive ventilation or high flow oxygenation, intubation [4]. A retrospective hospital-based cohort study of 585 French sarcoidosis patients in 2017, demonstrated an estimate of a 5 % frequency of severe infections that resulting in hospital admission and death [5]. A typical HRCT feature in sarcoidosis is the presence of well-defined micronodules scattered along the broncho-vascular bundle, veins, fissures and pleura in a characteristic lymphatic distribution. Occasionally, “galaxy sign”, a highly suggestive of pulmonary sarcoidosis (predominance of a mid-to-upper lung zones) may demonstrates conglomerate masses that are surrounded by a multitude of micronodules (Figure 3) [6].

Where VDR dominantly connected to 14 different kinds of drug, protein drug interaction network collected from DrugBank provides proper treatment. Vitamin D and some of its analogous compounds might play significant roles in modulating both COVID-19 and sarcoidosis conditions is indicated by this network (Figure 4) [3].

Besides sarcoidosis of lungs, symptomatic and accidental extrapulmonary sarcoidosis is also found around the world (Figures 5-7) [7-9].

In conclusion, hub gene identification might have significant roles in modulating sarcoidosis and COVID-19 infection. In the literature, cases with sarcoid-like granuloma have been reported very few. Sarcoid-like immune response to COVID-19 could be noncaseating granulomas due to short time from disease to develop granuloma.


  1. Galeotti C, Baryl J (2020) Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 16(8): 413-414.
  2. Racil H, Znegui T, Maazoui S, Touil A, Habibech S, Henda N, et al. (2023) Can coronavirus disease 2019 induce sarcoidosis: A case report. Thorac Res Pract 24(1): 45-48.
  3. Mogal R, Sovupa SA, Junayed A, Mahmod R, Abedin Z, Sikder S (2022) Common genetic aspects between COVID-19 and sarcoidosis: A network-based approach using expression data. Biochem Biophys Rep 29: 101219.
  4. Nadeem O, Sharma A, Alaouie D, Bradley P, Ouellette D (2021) Outcome in patients with sarcoidosis diagnosed with COVID-19. Presentation at Chest 2021 Annual Meeting, pp: 17-20.
  5. Dureault A, Chapelon C, Biard L, Domont F, Savey L, et al. (2017) Severe infections in sarcoidosis: Incidence, predictors and long-term outcome in a cohort of 585 patients. Medicine (Baltimore) 96: e8846.
  6. Bernardinello N, Petrarulo S, Balestro E, Cocconcelli E, Veltkamp M, Spagnolo P (2021) Pulmonary Sarcoidosis: Diagnosis and Differential Diagnosis. Diagnostics (Basel) 11(9):1558.
  7. Dhomps A, Thibault F, Streichenberger N, Andrea S, Jeremie T (2019) Isolated muscular sarcoidosis revealed by hypercalcemia. Clin Nucl Med 44(10): 824-825.
  8. Ashjan K, Darejan B, Lea F, Mathilde H, Vincent P, Imperiale, et al. (2024) 18F-FDG PET/MRI for diagnosis and treatment efficacy evaluation of spinal sarcoidosis. Clin Nucl Med 49(1): e28-e30.
  9. Alan S, Dagmar HS (2023) FDG PET of Isolated Right Ventricular Sarcoidosis. Clin Nucl Med 48(2): 184-185.